According to filings with the U.S. Securities and Exchange Commission, OS Therapies is raising up to $7,531,884.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About OS Therapies
OS Therapies (OST) is a clinical-stage cancer immunotherapy company focused on developing innovative treatments for osteosarcoma and other solid tumors. The company aims to activate the immune system to target cancers expressing HER2, addressing a critical need for new therapies in osteosarcoma, a disease that has seen no new treatments in over 30 years. Their lead program centers on HER2 targeted therapies, which activate killer T cells against all cancer antigens expressed by the tumor. Beyond osteosarcoma, OS Therapies plans to expand its therapeutic development into other cancers such as breast, esophageal, lung, ovarian, and pancreatic cancers, utilizing its HER2 target cancer immunotherapy and OST-tADC tunable Antibody Drug Conjugate silicone linker platform. A documentary featuring their OST-HER2 immunotherapy, Shelter Me: The Cancer Pioneers, received two 2025 Daytime Emmy nominations, highlighting the significance of their work.

To learn more about OS Therapies, visit https://ostherapies.com/
OS Therapies Linkedin Page: https://www.linkedin.com/company/os-therapies/

Contact:
Christopher Acevedo, Chief Financial Officer
410-297-7793
https://www.linkedin.com/in/christopher-acevedo-4a60a713/

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.